MRNA vaccine aims to prevent shingles in older adults

NCT ID NCT07400003

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new mRNA vaccine to prevent shingles (herpes zoster) in adults aged 40 and older. The vaccine uses mRNA technology, similar to some COVID-19 vaccines, and is freeze-dried for easier storage. Researchers will compare different doses against existing vaccines and a placebo to see which is safest and most effective at triggering immunity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lyophilized herpes zoster virus mRNA vaccine
What this could lead to: If successful, this could lead to a new, more effective shingles vaccine that is easier to store and transport.
What could go wrong: This is an early phase 1/2 trial, so safety and effectiveness are not yet proven. The vaccine may cause side effects or fail to generate a strong immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES ZOSTER MRNA VACCINE

Contacts and locations

Locations

Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention
RECRUITING

Xinjiang, 831100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.